HOUSTON, Sept. 28, 2023 /PRNewswire/ — Fabre-Kramer Pharmaceuticals Inc. (Fabre-Kramer), a biopharmaceutical company committed to developing novel therapies to address unmet needs in psychiatry and neurology, is pleased to announce that the U.S….Original Article
FDA Approves Exxua (gepirone) for the Treatment of Major Depressive Disorder in Adults
